UroGen Pharma (URGN) Net Income (QoQ) (2017 - 2026)
UroGen Pharma (URGN) Net Income (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | UroGen Pharma | 2.03 Bn | 1.89 Bn | 46.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -361.93% |
| Dec 31, 2025 | 126.99% |
| Sep 30, 2025 | 33.23% |
| Jun 30, 2025 | -13.91% |
| Mar 31, 2025 | -612.89% |
| Dec 31, 2024 | 74.02% |
| Sep 30, 2024 | 29.13% |
| Jun 30, 2024 | -3.46% |
| Mar 31, 2024 | -6,320.81% |
| Dec 31, 2023 | 102.37% |
| Sep 30, 2023 | 9.35% |
| Jun 30, 2023 | 20.11% |
| Mar 31, 2023 | -1,232.73% |
| Dec 31, 2022 | 91.22% |
| Sep 30, 2022 | 3.22% |
| Jun 30, 2022 | 5.99% |
| Mar 31, 2022 | -1,436.36% |
| Dec 31, 2021 | 93.88% |
| Sep 30, 2021 | -15.21% |
| Jun 30, 2021 | -1.11% |